Medicenna Therapeutics Corp is the development and commercialization of IL-2, IL-4 and IL-13 Superkines and empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its platforms are Superkine, BISCUIT, TEMASK, Publications, and Scientific Publications.